Organon & Co (NYSE:OGN)

$ 15.06 0.11 (0.74%) Market Cap: 3.85 Bil Enterprise Value: 11.78 Bil PE Ratio: 2.97 PB Ratio: 7.81 GF Score: 71/100

Q3 2024 Organon & Co Earnings Call Transcript
Oct 31, 2024

$18.78 (+4.74%)

Earnings
Q2 2024 Organon & Co Earnings Call Transcript
Aug 06, 2024

$18.65 (-7.63%)

Earnings
Q1 2024 Organon & Co Earnings Call Transcript
May 02, 2024

$19.5 (+3.56%)

Earnings
Q4 2023 Organon & Co Earnings Call Transcript
Feb 15, 2024

$18.62 (+13.81%)

Earnings
Organon & Co at JPMorgan Healthcare Conference Transcript
Jan 09, 2024
Organon & Co at Piper Sandler Healthcare Conference Transcript
Nov 29, 2023
Q3 2023 Organon & Co Earnings Call Transcript
Nov 02, 2023

$13.11 (-10.51%)

Earnings
Q2 2023 Organon & Co Earnings Call Transcript
Aug 08, 2023

$23.77 (+9.04%)

Earnings
Q1 2023 Organon & Co Earnings Call Transcript
May 04, 2023

$22.01 (-9.20%)

Earnings
Q4 2022 Organon & Co Earnings Call Transcript
Feb 16, 2023

$24.87 (-15.00%)

Earnings
Organon & Co at JPMorgan Healthcare Conference Transcript
Jan 10, 2023
Organon & Co at Piper Sandler Healthcare Conference Transcript
Nov 29, 2022
Q3 2022 Organon & Co Earnings Call Transcript
Nov 03, 2022

$25.88 (-0.19%)

Earnings
Q2 2022 Organon & Co Earnings Call Transcript
Aug 04, 2022

$32.41 (-0.49%)

Earnings
Q1 2022 Organon & Co Earnings Call Transcript
May 05, 2022

$34.87 (+5.06%)

Earnings
Organon & Co at Cowen Health Care Conference (Virtual) Transcript
Mar 09, 2022
Q4 2021 Organon & Co Earnings Call Transcript
Feb 17, 2022

$36.37 (+0.08%)

Earnings
Organon & Co at JPMorgan Healthcare Conference Transcript
Jan 10, 2022
Organon & Co at Evercore ISI HealthCONx Virtual Conference Transcript
Dec 01, 2021
Q3 2021 Organon & Co Earnings Call Transcript
Nov 11, 2021

$34.72 (-5.21%)

Earnings
Organon & Co at Morgan Stanley Global Healthcare Conference (Fireside Chat) Transcript
Sep 13, 2021
Q2 2021 Organon & Co Earnings Call Transcript
Aug 12, 2021

$33.5 (+11.93%)

Earnings

Organon & Co at JPMorgan Healthcare Conference Transcript

Jan 10, 2022 / 07:15PM GMT

Release Date Price: $32.21 (-0.62%)

Transcript

Christopher Thomas Schott

JPMorgan Chase & Co, Research Division - Senior Analyst

Good afternoon, everybody. I'm Chris Schott at JPMorgan, and it's my pleasure to be hosting a fireside chat with the Organon management team today. From the company, we have Kevin Ali, the company's CFO (sic -- CEO); as well as Matt Walsh, the company's CFO. So Kevin and Matt, Happy New Year, and thanks for speaking with us today.

Kevin Ali

Organon & Co. - CEO & Director

A pleasure.

Christopher Thomas Schott

JPMorgan Chase & Co, Research Division - Senior Analyst

Excellent. Well, this is your first presentation at the JPMorgan Healthcare Conference post the Merck spin. And would love to maybe kick off the conversation with just some opening remarks from both of you as you think about Organon's positioning, as we think about the -- kind of the spin out of Merck and heading into 2022. So with that, maybe turn it over to Kevin.

Kevin Ali

Organon & Co. - CEO & Director

Already have an account? Log in

Get the full story

Start 7-Day Free Trial

	Access to All Earning Calls and Stock Analysis
	30-Year Financial on one screen
	All-in-one Stock Screener with unlimited filters
	Customizable Stock Dashboard
	Real Time Insider Trading Transactions
	8,000+ Institutional investors’ 13F holdings
	Powerful Excel Add-in and Google sheets Add-on
	All data downloadable
	Quick customer support
	And much more...

30-Day 100% money back guarantee

You are not charged until the trial ends. Subscription fee may be tax deductible.

Excellent

4.6 out of 5

Trustpilot

Research Tools

All-In-One Screener Stock Ideas Stock List Guru List Guru Real-Time Picks Insider List Insider Trades Economic Indicators Sector & Industry Performance DCF Calculator Discussion Board

Product

Pricing Plans Excel Add-In Google Sheets Add-on Data API Stock Comparison Table Manual of Stocks Mobile App 中文

Education

Financial Glossary Tutorials FAQ Schedule Free Session Buffett Indicator Shiller P/E Yield Curve Today U.S. Inflation Rate Global Market Valuation Fed Net Liquidity Buffett Assets Allocation

Company

About GuruFocus Career Contact Us Advertise Site Map Term of Use Privacy Policy Referral Program Partner Program

Survey

We'd love to learn more about your experiences on GuruFocus.com and how we can improve!

Take Survey

Disclaimers

GuruFocus.com is not operated by a broker or a dealer. Under no circumstances does any information posted on GuruFocus.com represent a recommendation to buy or sell a security. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The individuals or entities selected as "gurus" may buy and sell securities before and after any particular article and report and information herein is published, with respect to the securities discussed in any article and report posted herein. Gurus may be added or dropped from the GuruFocus site at any time. In no event shall GuruFocus.com be liable to any member, guest or third party for any damages of any kind arising out of the use of any content or other material published or available on GuruFocus.com, or relating to the use of, or inability to use, GuruFocus.com or any content, including, without limitation, any investment losses, lost profits, lost opportunity, special, incidental, indirect, consequential or punitive damages. Past performance is a poor indicator of future performance. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The information on this site is in no way guaranteed for completeness, accuracy or in any other way. The gurus listed in this website are not affiliated with GuruFocus.com, LLC. Stock quotes are provided by QuoteMedia, Inc. (CSI). Company fundamental data is provided by Morningstar. Analyst estimates data is sourced from both Refinitiv and Morningstar, with priority given to Refinitiv data. Data is updated daily.